Corporate governance covers the overall principles concerning the interests of the shareholders, which strive for transparency and accountability. Cytos Biotechnology is fully committed to good corporate governance. Cytos Biotechnology’s principles and rules on corporate governance are outlined in the corporate governance section of the Annual Report 2009 and the Articles of Association accessible below.
 

Committees

The Audit Committee: The Board of Directors has established the Audit Committee as a permanent committee to carry out specific duties. It consists of three members of the Board of Directors, and among other aspects, reviews the performance of external auditors, assesses the quality of internal control systems and forms an opinion on the state of compliance with norms within the company.

Current members are: Othmar T. Vock – Chairman of the Audit Committee; Sir Mark Richmond, PhD, ScD; Jakob Schlapbach, lic. rer. pol. & MBA.
For members' biographies see section Management Team/The Board of Directors.

The Nomination and Compensation Committee: The Board of Directors has established the Nomination and Compensation Committee as a permanent committee to carry out specific duties. It consists of three members of the Board of Directors, and among other aspects, proposes new members of the Executive Board, determines the remuneration of the Executive Board and the Board of Directors and proposes the remuneration policy to the Board of Directors.

Current members are: Thorlef Spickschen, Dr. rer. pol. – Chairman of the Nomination and Compensation Committee; Thomas Hecht, MD; Jean-Yves le Cotonnec, MD, PhD.
For members' biographies see section Management Team/The Board of Directors.